COST-EFFECTIVENESS OF VEDOLIZUMAB FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS IN THAILAND

被引：0
|
作者：
Sruamsiri, R. [1 ]
机构：
[1] Takeda Thailand Ltd, Bangkok, Thailand
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.07.015
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CE3
引用
收藏
页码：S2 / S2
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH INFLIXIMAB, ADALIMUMAB, GOLIMUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS IN GERMANY
    Quon, P.
    Sardesai, A.
    Milev, S.
    DiBonaventura, M.
    Cappelleri, J. C.
    Kisser, A.
    Modesto, I
    Dietz, L.
    Dignass, A.
    Bargo, D.
    VALUE IN HEALTH, 2019, 22 : S617 - S617
  • [22] A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis
    Tsai, Her Hsin
    Black, Christopher
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (06) : 679 - 683
  • [23] COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER BIOLOGIC FAILURE OR INTOLERANCE IN SPAIN
    Menchen, L.
    de Andres-Nogales, F.
    Garcia, S.
    Sanchez-Guerrero, A.
    Menchen, B.
    Cabez, A.
    Gomez, S.
    Lopez, A.
    Casado, M. A.
    Peral, C.
    Taxonera, C.
    VALUE IN HEALTH, 2019, 22 : S619 - S619
  • [24] Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
    Feagan, Brian G.
    Schreiber, Stefan
    Wolf, Douglas C.
    Axler, Jeffrey L.
    Kaviya, Arpeat
    James, Alexandra
    Curtis, Rebecca I.
    Geransar, Parnia
    Stallmach, Andreas
    Ehehalt, Robert
    Bokemeyer, Bernd
    Khalid, Javaria Mona
    O'Byrne, Sharon
    INFLAMMATORY BOWEL DISEASES, 2019, 25 (06) : 1028 - 1035
  • [25] Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany
    Sardesai, Aditya
    Dignass, Axel
    Quon, Peter
    Milev, Sandra
    Cappelleri, Joseph C.
    Kisser, Agnes
    Modesto, Irene
    Sharma, Puza P.
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 279 - 290
  • [26] Economic evaluation of vedolizumab SC for the treatment of moderate-to-severe ulcerative colitis in Canada
    Fischer, A.
    Oppe, M.
    Stypa, S.
    Lukyanov, V.
    Petrakis, I.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S387 - S387
  • [27] COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN COLOMBIA
    Hansen, Tawnya
    Mak, Joyce
    Underwood, Fox
    Windsor, Joseph
    King, James
    Quan, Joshua
    Buie, Michael
    Coward, Stephanie
    Frolkis, Alex
    Leung, Alexander
    Ma, Christopher
    Novak, Kerri
    Panaccione, Remo
    Qian, Yiming
    Burisch, Johan
    Gearry, Richard
    Ng, Siew
    Kaplan, Gilaad
    INFLAMMATORY BOWEL DISEASES, 2022, 28 : S44 - S44
  • [28] COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN COLOMBIA
    Gil, Fabio
    Julian-Banos, Fabian
    Amador, Luisa
    Castano, Natalia
    Reyes, Juan
    GASTROENTEROLOGY, 2022, 162 (03) : S44 - S44
  • [29] Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece
    Vellopoulou, Katerina
    Stefanou, Garyfallia
    Tzanetakos, Charalampos
    Boubouchairopoulou, Nantia
    Nakou, Magdalini
    Gourzoulidis, George
    Kourlaba, Georgia
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (03) : 325 - 333
  • [30] Spotlight: Pharmacological Management of Moderate-to-Severe Ulcerative Colitis
    Singh, Siddharth
    Loftus Jr, Edward V.
    Limketkai, Berkeley N.
    Haydek, John P.
    Agrawalm, Manasi
    Scott, Frank I.
    Ananthakrishnan, Ashwin N.
    GASTROENTEROLOGY, 2024, 167 (07) : 1344 - 1344
12345